Scientific Opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

EFSA Journal

Volumn 9, Issue 7, 2011, Pages

[No Author Info available]

Author keywords

health claims; LDL cholesterol; Monacolin K; Monascus purpureus; red yeast rice

Indexed keywords

EID: 84927728357     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2011.2304     Document Type: Article

References (6)

1. Gordon RY, Cooperman T, Obermeyer W and Becker DJ, 2010. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Archives of Internal Medicine, 170, 1722–1727.
2. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM and Go VL, 1999. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. American Journal of Clinical Nutrition, 69, 231–236.
3. Li YG, Zhang F, Wang ZT and Hu ZB, 2004. Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 35, 1101–1112.
4. Lin CC, Li TC and Lai MM, 2005. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. European Journal of Endocrinology, 153, 679–686.
5. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T and Fønnebø V, 2006. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinese Medicine, 1, 4.
6. Man RYK, Lynn EG, Cheung F, Tsang PSY and Karmin O, 2002. Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2). Molecular and Cellular Biochemistry, 233, 153–158.